| abstract |
Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Rituximab, trastuzumab and anti-CTLA4 antibodies are typical monoclonal antibodies that may be used. The enhanced anti-tumor activity of the combination therapy may be tolerate monoclonal therapy, relapse after being treated with monoclonal antibodies, or the enhanced IL-21 anti-tumor effect may be associated with treatment with monoclonal antibodies. Particularly useful for the patient population in case of reduction. n n Monoclonal antibody, IL-21, cancer treatment, rituximab, trastuzumab, cytotoxicity |